MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Charts Explain Top Health Industry Issues In 2015 (#5)

5. Putting a Price For Positive Outcomes Providers and insurers are all reluctant to pay for high drug prices unless the drugmakers can actually prove that they are improving clinical outcomes for patients and/or lowering costs. While the PwC report focuses on drugs, device makers are also faced with the same challenging market. Gone are the days when device vendors could simply tweak an existing product, add a bell or a whistle, and then charge a premium and have no one blink.

5. Putting a Price For Positive Outcomes

Providers and insurers are all reluctant to pay for high drug prices unless the drugmakers can actually prove that they are improving clinical outcomes for patients and/or lowering costs. While the PwC report focuses on drugs, device makers are also faced with the same challenging market. Gone are the days when device vendors could simply tweak an existing product, add a bell or a whistle, and then charge a premium and have no one blink.

Now drugmakers and device makers alike need to prove to payors and providers that their products improve clinical outcomes and also lowers overall costs, a tall order.

Even new advances are often not guaranteed success. Genomics has made remarkable progress in the past couple of years bringing the promise of personalized medicine a little closer to reality. But they still have a ways to go to convince the average consumer to pay for it.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish